Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.

Yu A, Wu S, Zhang Z, Dening T, Zhao S, Pinner G, Xia J, Yang D.

Cochrane Database Syst Rev. 2018 Jun 28;6:CD012494. doi: 10.1002/14651858.CD012494.pub2. Review.

PMID:
29952000
2.

Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia.

Lim EY, Yang DW, Kim JS, Cho AH.

J Korean Med Sci. 2018 Apr 13;33(19):e133. doi: 10.3346/jkms.2018.33.e133. eCollection 2018 May 7.

3.

Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease.

Alonge O, Iqbal FM, Cifonelli E.

BMJ Case Rep. 2018 Apr 17;2018. pii: bcr-2018-224597. doi: 10.1136/bcr-2018-224597. Review.

PMID:
29666099
4.

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.

Muñoz-Moreno JA, Prats A, Moltó J, Garolera M, Pérez-Álvarez N, Díez-Quevedo C, Miranda C, Fumaz CR, Ferrer MJ, Clotet B; TRIANT-TE Study Group.

PLoS One. 2017 Aug 30;12(8):e0182547. doi: 10.1371/journal.pone.0182547. eCollection 2017.

5.

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Park KW, Kim EJ, Han HJ, Shim YS, Kwon JC, Ku BD, Park KH, Yi HA, Kim KK, Yang DW, Lee HW, Kang H, Kwon OD, Kim S, Lee JH, Chung EJ, Park SW, Park MY, Yoon B, Kim BC, Seo SW, Choi SH.

PLoS One. 2017 Aug 7;12(8):e0182123. doi: 10.1371/journal.pone.0182123. eCollection 2017.

6.

Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.

Mohammad D, Chan P, Bradley J, Lanctôt K, Herrmann N.

Expert Opin Drug Saf. 2017 Sep;16(9):1009-1019. doi: 10.1080/14740338.2017.1351540. Epub 2017 Jul 12. Review.

PMID:
28678552
7.

Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.

Servello A, Ettorre E, Cacciafesta M.

Panminerva Med. 2017 Sep;59(3):275-277. doi: 10.23736/S0031-0808.17.03274-8. No abstract available.

PMID:
28665099
8.

Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.

Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T.

Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.

PMID:
28594244
9.

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease.

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

PMID:
28452906
10.

Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.

Yasutaka Y, Fujioka S, Terasawa M, Shibaguchi H, Futagami K, Ouma S, Tsuboi Y, Kamimura H.

Yakugaku Zasshi. 2017;137(1):121-125. doi: 10.1248/yakushi.16-00206. Japanese.

11.

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.

Wang L, Wang Y, Tian Y, Shang J, Sun X, Chen H, Wang H, Tan W.

Bioorg Med Chem. 2017 Jan 1;25(1):360-371. doi: 10.1016/j.bmc.2016.11.002. Epub 2016 Nov 5.

PMID:
27856236
12.

Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.

Lampela P, Tolppanen AM, Tanskanen A, Tiihonen J, Lavikainen P, Hartikainen S, Taipale H.

Ann Med. 2017 May;49(3):230-239. doi: 10.1080/07853890.2016.1254349. Epub 2016 Nov 29.

PMID:
27786552
13.

Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.

Morgan TM, Soh B.

Br J Clin Pharmacol. 2017 Mar;83(3):510-516. doi: 10.1111/bcp.13133. Epub 2016 Oct 26.

14.
15.

Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.

Spiridigliozzi GA, Hart SJ, Heller JH, Schneider HE, Baker JA, Weadon C, Capone GT, Kishnani PS.

Am J Med Genet A. 2016 Jun;170(6):1545-55. doi: 10.1002/ajmg.a.37650. Epub 2016 Apr 8.

PMID:
27061338
16.

Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.

Soysal P, Isik AT.

J Nutr Health Aging. 2016 Apr;20(4):398-403. doi: 10.1007/s12603-015-0603-z.

PMID:
26999239
17.

Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.

Thornton SL, Pchelnikova JL, Cantrell FL.

J Pediatr. 2016 May;172:147-50. doi: 10.1016/j.jpeds.2016.01.056. Epub 2016 Feb 28.

PMID:
26935787
18.

Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.

Nieto RA, Deardorff WJ, Grossberg GT.

Expert Opin Pharmacother. 2016;17(6):861-70. doi: 10.1517/14656566.2016.1159296.

PMID:
26918774
19.

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y.

Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13.

20.

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.

Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K.

Int J Geriatr Psychiatry. 2016 Aug;31(8):892-904. doi: 10.1002/gps.4405. Epub 2015 Dec 17. Review.

Supplemental Content

Loading ...
Support Center